Plerixafor

In the US, Plerixafor (plerixafor systemic) is a member of the following drug classes: hematopoietic stem cell mobilizer, other immunostimulants and is used to treat Multiple Myeloma and Non-Hodgkin's Lymphoma.

US matches:

• Plerixafor
• Plerixafor Subcutaneous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L03AX16

CAS registry number (Chemical Abstracts Service)

0110078-46-1

Chemical Formula

C28-H54-N8

Molecular Weight

502

Therapeutic Category

Antineoplastic agent

Chemical Names

1,1'-(1,4-phenylenebismethylene)bis(1,4,8,11-tetraazacyclotetradecane) (WHO)

1,4,8,11-Tetraazacyclotetradecane, 1,1'-[1,4-phenylenebis(methylene)]bis- (USAN)

Foreign Names

• Plerixaforum (Latin)
• Plerixafor (German)
• Plérixafor (French)
• Plerixafor (Spanish)

Generic Names

• Plerixafor (OS: USAN)
• AMD3100 (IS)
• JM 3100 (IS)
• SDZ-SID-791 (IS)
• UNII-S915P5499N (IS)

Brand Names

• Mozobil
  Genzyme, Austria; Genzyme, Belgium; Genzyme, Germany; Genzyme, Spain; Genzyme, Finland; Genzyme, France; Genzyme, United Kingdom; Genzyme, Greece; Genzyme, Israel; Genzyme, Iceland; Genzyme, Latvia; Genzyme, Netherlands; Genzyme, Norway; Genzyme, Sweden; Genzyme, Slovenia; Genzyme, United States; Medical Intertrade, Croatia (Hrvatska)

International Drug Name Search

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.